The basic antigen G250 (carbonic anhydrase IX; CAIX) is expressed on the surface of 75% of RCC cells (90% of clear renal cell carcinoma) but has minimal expression in normal cells (121, 122), so that it can become one of the possible therapeutic targets. This evidence concerns the gene CA9 and renal cell adenocarcinoma.